Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Prodrug
Glycerol phenylbutyrate
Другие языки:

    Glycerol phenylbutyrate

    Подписчиков: 0, рейтинг: 0
    Glycerol phenylbutyrate
    Glycerol phenylbutyrate skeletal.svg
    Clinical data
    Trade names Ravicti
    AHFS/Drugs.com Micromedex Detailed Consumer Information
    License data
    Routes of
    administration    		 By mouth
    ATC code
    Legal status
    Legal status
    Identifiers
    • 1,2,3-Propanetriyl tris(4-phenylbutanoate)
    CAS Number
    PubChem CID
    DrugBank
    ChemSpider
    UNII
    ChEMBL
    CompTox Dashboard (EPA)
    ECHA InfoCard 100.228.552
    Chemical and physical data
    Formula C33H38O6
    Molar mass 530.661 g·mol−1
    3D model (JSmol)
    • C1=CC=C(C=C1)CCCC(=O)OCC(COC(=O)CCCC2=CC=CC=C2)OC(=O)CCCC3=CC=CC=C3
    • InChI=1S/C33H38O6/c34-31(22-10-19-27-13-4-1-5-14-27)37-25-30(39-33(36)24-12-21-29-17-8-3-9-18-29)26-38-32(35)23-11-20-28-15-6-2-7-16-28/h1-9,13-18,30H,10-12,19-26H2
    • Key:ZSDBFLMJVAGKOU-UHFFFAOYSA-N

    Glycerol phenylbutyrate (USAN), trade name Ravicti, is a medication used in the treatment of certain inborn urea cycle disorders. The medication works by preventing the harmful buildup of ammonia in the body. It is an FDA-approved prescription drug in the US. It is approved for anyone over 2 months of age. It was developed by Hyperion Therapeutics based on the existing drug Buphenyl, and received approval on February 1, 2013. Hyperion has been criticized for setting a high price for the drug. The price was set at US$250,000–290,000. In 2014, the drug generated $30.8 million in net sales, far behind the older and less expensive Buphenyl ($113.6 million in sales). In March 2015, Horizon Pharma acquired Hyperion Therapeutics and thus Raviciti.

    External links


    Новое сообщение